Dendrite International Selected by Bristol-Myers Squibb Company for Strategic Sales & Marketing Initiative.

Business Editors

MORRISTOWN, N.J.--(BUSINESS WIRE)--Jan. 16, 2001

Multi-year contract to provide comprehensive services and support

to the fourth largest pharmaceutical sales force in the US

Dendrite International, Inc., the leading provider of pharmaceutical CRM solutions, analytics, data and sales support services for the worldwide pharmaceutical industry (NASDAQ/NMS: DRTE), today announced that it has been selected by Bristol-Myers Squibb Company to become their key service provider in the design and implementation of the company's sales and marketing infrastructure. The agreement calls for Dendrite to provide support and services to Bristol-Myers Squibb's US pharmaceutical sales force.

Specifically, the agreement calls for Dendrite to provide licenses and services for Dendrite's WebForce(TM) solution with embedded Force Analyzer(TM), training and technical support services. In addition, the Dendrite implementation will integrate a national expense tracking system as well as an enhanced sample management system into the WebForce(TM) offering.

"Bristol-Myers Squibb Company selected Dendrite after a thorough evaluation of alternative suppliers available in the market. This agreement reinforces Dendrite's commitment to build vertically integrated systems that comprehensively address several sales force related issues. Combined with our focus on customer satisfaction and pharma knowledge, these solutions further position Dendrite as the recognized leader in improving sales force productivity and effectiveness globally," stated John Bailye, chairman and CEO, Dendrite International. "We look forward to continuing our business relationship with Bristol-Myers Squibb Company."

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is a $20 billion diversified, worldwide health and personal care company whose principal businesses are medicines and nutritionals. The Company mission is to develop and market innovative products that extend and enhance human life.

About Dendrite

Dendrite International, Inc. (NASDAQ/NMS:DRTE) designs and supports technology-based knowledge systems that enhance the competitive activities of the sales forces of the world's largest pharmaceutical companies. Over one-third of all pharmaceutical sales representatives and their managers worldwide rely on Dendrite. Headquartered in Morristown, New Jersey, Dendrite employs over 1500 people around the world. For more information, visit the Company's Web site at http://www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This press release contains statements that are forward-looking statements and discuss expectations about future events or outcomes with respect to Dendrite and its business, including statements regarding expected results for future periods. We believe these statements are within the scope of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that these statements be covered by the safe harbors created by such acts. The forward-looking statements are based on our current expectations, assumptions, estimates and projections about our company and the pharmaceutical and consumer packaged goods industries and involve risks and uncertainties. Accordingly, Dendrite's actual results may differ materially from the results discussed in or implied by such forward-looking statements. The risk factors that could cause actual results to differ from the results expressed or implied by these forward-looking statements include the following: (i) our business is heavily dependent on the pharmaceutical industry; (ii) our quarterly results of operations may fluctuate significantly and may not meet market expectations; (iii) our lengthy sales and implementation cycles make it difficult to predict our quarterly revenues; (iv) our fixed costs may lead to fluctuations in our quarterly operating results if revenues fall below expectations; (v) our business is affected by variations in our customers' budget cycles; (vi) our revenues would decline and our business would be adversely affected by the loss of one of our major customers; (vii) we may be unable to successfully introduce new products or respond to technological change; (viii) timing of revenue recognition is dependent of many factors including timing of customer acceptance of product offerings and execution of contracts for Dendrite products, which factors are often outside the Company's control and which cannot always be predicted;(ix) increased competition may result in price reductions and decreased demand for our products and services; (x) some of our customers rely on our competitors for market data; (xi) our international operations have risks that our domestic operations do not; (xii) our success depends on retaining our key senior management team and on attracting and retaining qualified personnel; (xiii) our inability to manage our growth could adversely affect our business; (xiv) our business depends on proprietary technology that we may not be to protect completely; and (xv) the consumer packaged goods industry may have different characteristics from those we are used to in the pharmaceutical industry. In light of the significant uncertainties inherent in these forward-looking statements, you should not consider their inclusion as a representation by us or anyone else that we will achieve our objectives and plans. Moreover, we assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. For further discussion of these and other factors that could adversely affect Dendrite's financial condition and results of operations consult Dendrite's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.